N,N-Bis-[2-(2,2,2-trifluoro-acetylamino)-ethyl]-succinamic acid | 808112-87-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N-Bis-[2-(2,2,2-trifluoro-acetylamino)-ethyl]-succinamic acid
• 英文别名: 4-{Bis[2-(2,2,2-trifluoroacetamido)ethyl]amino}-4-oxobutanoic acid；4-[bis[2-[(2,2,2-trifluoroacetyl)amino]ethyl]amino]-4-oxobutanoic acid
• CAS: 808112-87-0
• 化学式: C₁₂H₁₅F₆N₃O₅
• 分子量: 395.259
• InChiKey: OYDVGPLLVCKJKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  N,N-Bis-[2-(2,2,2-trifluoro-acetylamino)-ethyl]-succinamic acid 在 水 、 N,N'-二异丙基碳二亚胺 作用下， 以 乙腈 为溶剂， 反应 28.0h， 生成 N,N-Bis[2-[4-oxo-4-[bis[2-(trifluoroacetylamino)ethyl]amino]butyrylamino]ethyl]-6-(benzyloxycarbonylamino)hexanamide
  参考文献：
  名称：

  Dendrimeric Molecular Transporters:  Synthesis and Evaluation of Tunable Polyguanidino Dendrimers That Facilitate Cellular Uptake

  摘要：

  [GRAPHICS]Nine fluorescently labeled structurally varied polyguanidino dendrimers based on diamino acid monomeric units were individually synthesized in an efficient, scalable sequence using a trifluoroacetamide protecting group-perguanidinylation strategy. While the dendrimers varied significantly in their ability to enter a human lymphocyte cell line, the best transporters out-performed an oligoarginine reference standard.

  DOI：

  10.1021/ol051496y
• 作为产物：
  描述：

  丁二酸酐 、 2,2,2-trifluoro-N-[2-({2-[(trifluoroacetyl)amino]ethyl}amino)ethyl]acetamide 以 乙腈 为溶剂， 反应 20.0h， 生成 N,N-Bis-[2-(2,2,2-trifluoro-acetylamino)-ethyl]-succinamic acid
  参考文献：
  名称：

  Dendrimeric Molecular Transporters:  Synthesis and Evaluation of Tunable Polyguanidino Dendrimers That Facilitate Cellular Uptake

  摘要：

  [GRAPHICS]Nine fluorescently labeled structurally varied polyguanidino dendrimers based on diamino acid monomeric units were individually synthesized in an efficient, scalable sequence using a trifluoroacetamide protecting group-perguanidinylation strategy. While the dendrimers varied significantly in their ability to enter a human lymphocyte cell line, the best transporters out-performed an oligoarginine reference standard.

  DOI：

  10.1021/ol051496y

文献信息

• Gastrin releasing peptide compounds
  申请人：——

  公开号：US20040253225A1

  公开（公告）日：2004-12-16

  New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

  本发明提供了用于诊断成像或治疗的新型化合物，其化学式为M-N—O—P-G，其中M是光学标记物或金属螯合剂（形式上与金属放射性核素络合或未络合），N—O—P是连接剂，G是GRP受体靶向肽。本发明还提供了使用该化合物对患者进行成像和/或提供放射治疗或光治疗的方法。还提供了制备诊断成像剂的方法和试剂盒。还提供了制备放射治疗剂的方法和试剂盒。
• Gastrin Releasing Peptide Compounds
  申请人：Cappelletti Enrico

  公开号：US20080008649A1

  公开（公告）日：2008-01-10

  New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R 1 -R 5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided. Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer, methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for facilitating combination therapy in patients with hormone sensitive prostate cancer and for decreasing aberrant vascular permeability in patients with hormone sensitive prostate cancer.

  新的和改进的化合物可用于诊断成像或治疗，其化学式为M-N—O—P-G，其中M是具有以下结构的金属螯合剂： 其中R1-R5和FG如此定义（以金属放射性核素或未配合的形式），N—O—P是含有至少一个非α氨基酸环状基团、至少一个取代胆酸或至少一个非α氨基酸的连接物，而G是GRP受体靶向肽。在首选实施例中，M是Aazta金属螯合剂或其衍生物。本发明还提供了使用该化合物对患者进行成像和/或提供放射治疗或光治疗的方法。还提供了制备诊断成像试剂的方法和试剂盒。还提供了制备放射治疗试剂的方法和试剂盒。还提供了治疗前列腺肿瘤或延缓前列腺肿瘤进展的新方法，包括治疗前列腺癌骨骼或软组织转移的方法，治疗激素敏感和激素难治性前列腺癌的方法，延缓激素敏感前列腺癌进展的方法，促进激素敏感前列腺癌患者联合治疗的方法以及降低激素敏感前列腺癌患者异常血管渗透性的方法。
• GASTRIN RELEASING PEPTIDE COMPOUNDS
  申请人：Cappelletti Enrico

  公开号：US20110052491A1

  公开（公告）日：2011-03-03

  New and improved compounds for use in diagnostic imaging or therapy having the formula M—N—O—P—G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

  本发明涉及用于诊断成像或治疗的新型化合物，其化学式为M—N—O—P—G，其中M是光学标记或金属螯合剂（以与金属放射性核素形成络合物或非络合形式存在），N—O—P是连接剂，G是GRP受体靶向肽。本发明还提供了使用该化合物进行患者成像和/或提供放射治疗或光疗的方法。本发明还提供了制备诊断成像剂的方法和试剂盒。本发明还提供了制备放射治疗剂的方法和试剂盒。
• Labeled gastrin releasing peptides (GRP)
  申请人：Bracco Imaging S.p.A

  公开号：EP2281580A2

  公开（公告）日：2011-02-09

  New and improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent is further provided.

  用于诊断成像或治疗的新型改良化合物，其分子式为 M-N-O-P-G，其中 M 为光学标记或金属螯合剂（与金属放射性核素络合与否），N-O-P 为连接体，G 为 GRP 受体靶向肽。还提供了使用本发明化合物为患者成像和/或为患者提供放疗或光疗的方法。还提供了用本发明化合物制备诊断成像剂的方法和试剂盒。还提供了制备放射治疗剂的方法和试剂盒。
• Improved Gastrin Releasing Peptide Receptor-Binding Compounds
  申请人：Bracco Imaging S.p.A

  公开号：EP2500040A1

  公开（公告）日：2012-09-19

  New and improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent is further provided.

  用于诊断成像或治疗的新型改良化合物，其分子式为 M-N-O-P-G，其中 M 为光学标记或金属螯合剂（与金属放射性核素络合与否），N-O-P 为连接体，G 为 GRP 受体靶向肽。还提供了使用本发明化合物为患者成像和/或为患者提供放疗或光疗的方法。还提供了用本发明化合物制备诊断成像剂的方法和试剂盒。还提供了制备放射治疗剂的方法和试剂盒。